Biogen (BIIB)

Executive Summary

Biogen is a leading biotechnology company with a strong legacy in neurology, particularly multiple sclerosis (MS) through drugs like Tecfidera and Tysabri, and more recently in Alzheimer's disease with Leqembi (lecanemab), which received full FDA approval in 2023. The company faces headwinds from declining MS revenues due to generic competition, but Leqembi's launch is gaining traction, with growing physician adoption and expanded access. Biogen is also advancing a pipeline targeting neurodegenerative diseases, including Parkinson's, ALS, and rare genetic disorders. Key near-term catalysts include Phase 3 data for BIIB122 (a LRRK2 inhibitor for Parkinson's), potential FDA approval of a subcutaneous formulation of Leqembi to improve patient convenience, and proof-of-concept data for BIIB080 (an antisense oligonucleotide targeting tau in Alzheimer's). Despite challenges, Biogen's focus on high-unmet-need CNS indications and its commercial infrastructure position it for a turnaround, albeit with execution risks.

Upcoming Catalysts (preview)

• H2 2026Phase 3 data readout for BIIB122 (LRRK2 inhibitor) in Parkinson's disease60% success
• Q3 2026FDA decision on subcutaneous Leqembi (lecanemab) for Alzheimer's75% success
• 2026Phase 2 data for BIIB080 (MAPT antisense) in Alzheimer's disease40% success